rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CSTL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Castle Biosciences at Stephens conference: growth broadens beyond melanoma
      9h agoInvesting.comCSTL
      Castle Biosciences CEO Maetzold sells $464,870 in shares
      Nov 16Investing.comCSTL
      Castle Biosciences (CSTL) Lifts Guidance Following Revenue Growth But Is The Valuation Already Priced In

      Castle Biosciences (CSTL) came into focus for investors after management raised full year 2026 revenue guidance to a range of US$385 million to US$395 million, citing higher TissueCypher test volumes and better pricing. The raised guidance arrived alongside a share price that has been climbing in recent months, with a 90 day share price return of 16.44% and a 30 day share price return of 4.90%. However, the year to date share price return is still down 10.51% and the 5 year total shareholder...

      Nov 13Yahoo FinanceCSTL
      Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture
      Nov 12Yahoo FinanceCSTL
      Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference
      Nov 11Yahoo FinanceCSTL
      Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 37%: Here's is How to Trade
      Nov 10Yahoo FinanceCSTL
      Castle Biosciences Stock Gets A Lift From Raised 2026 Outlook

      Castle Biosciences reported third quarter 2026 revenue of US$102.89 million compared with US$83.04 million a year earlier, with a quarterly net loss of US$4.1 million and loss per share of US$0.13. The business raised its 2026 revenue outlook to a range of US$385 million to US$395 million and is pointing to positive adjusted EBITDA, supported by strong TissueCypher test adoption. We will look at how Castle Biosciences' investment narrative evolves as raised 2026 revenue guidance reshapes...

      Nov 6Yahoo FinanceCSTL
      Castle Biosciences, Inc. Q3 2026 Earnings Call Summary
      Nov 6Yahoo FinanceCSTL
      Castle Biosciences Inc (CSTL) (Q3 2026) Earnings Call Highlights: Revenue Jumps 24% as ...

      Castle Biosciences Inc (CSTL) raised full-year 2026 revenue guidance to $385-$395 million on strong TissueCypher growth, even as DecisionDx SCC pressures and a Q3 net loss temper the outlook.

      Nov 6Yahoo FinanceCSTL
      What Castle Biosciences (CSTL) Said on Its Q3 Earnings Call
      Nov 6Yahoo FinanceCSTL
      Castle Biosciences Q3 2026 Earnings Call Transcript
      Nov 5BenzingaCSTL
      Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Beats Revenue Estimates
      Nov 5Yahoo FinanceCRBUCSTL
      Castle Biosciences Reports Third Quarter 2026 Results
      Nov 5Yahoo FinanceCSTL
      Mizuho initiates Castle Biosciences stock with Outperform rating
      Oct 29Investing.comCSTL
      Tobin Juvenal, Castle Biosciences CCO, sells $108,767 in stock
      Oct 28Investing.comCSTL
      Castle Biosciences to Participate in Upcoming Investor Conferences

      Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Stephens Annual Investment Conference on Wednesday, Nov. 18, 2026, at 12:30 p.m. Central time.

      Oct 28Yahoo FinanceCSTL
      Castle Biosciences CEO Derek Maetzold sells $462,567 in stock
      Oct 22Investing.comCSTL
      Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026
      Oct 15Yahoo FinanceCSTL
      Castle Biosciences CCO Tobin sells $110,608 in stock
      Oct 15Investing.comCSTL
      Castle Biosciences presents Barrett’s esophagus test data at ACG
      Oct 12Investing.comCSTL
      Castle Biosciences president and CEO Derek Maetzold sells $515k stock
      Oct 11Investing.comCSTL
      New Melanoma Study Backing DecisionDx-Melanoma Could Be A Game Changer For Castle Biosciences (CSTL)
      Oct 9Yahoo FinanceCSTL
      Castle Biosciences CEO sells $512k in stock
      Sep 27Investing.comCSTL
      Roth MKM Keeps Their Buy Rating on Castle Biosciences (CSTL)

      Detailed price information for Castle Biosciences Inc (CSTL-Q) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailCSTL
      Castle Biosciences opens 55,000 sq ft Arizona lab facility
      Sep 22Investing.comCSTL
      Castle Biosciences to Open New Lab in Arizona
      Sep 22Yahoo FinanceCSTL
      Castle Biosciences to Open New Laboratory Facility in Scottsdale
      Sep 22Yahoo FinanceCSTL
      Castle Biosciences TissueCypher Study Shows Improved Risk-Aligned Barrett’s Esophagus Management

      A decision modeling study found that TissueCypher-guided care could increase appropriate treatment decisions for Barrett’s esophagus patients, including earlier escalation for non-dysplastic patients who later progress to high-grade dysplasia or cancer. Key Investor TakeawaysCastle Biosciences (NASDAQ:CSTL) reported a TissueCypher study showing appropriate Barrett’s esophagus management increased from 59.

      Sep 15Yahoo FinanceCSTL
      SciBase receives additional order from Castle Biosciences, advancing the collaboration

      SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has received an additional order for an acceleration of the current, ongoing clinical study and preparations for a second clinical study under the collaboration with Castle Biosciences. The order consists of both the portable Nevisense Go pen device and electrodes to a value of around $0.6 million or approximately MSEK 5.

      Sep 8Yahoo FinanceCSTL
      Castle Biosciences COO Oelschlager sells $138,642 in shares
      Sep 3Investing.comCSTL
      Castle Biosciences CCO Tobin Juvenal sells $51,190 in shares
      Sep 3Investing.comCSTL
      Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know

      Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.

      Aug 28Yahoo FinanceCSTL
      Castle Biosciences CCO Tobin W sells $317k in shares
      Aug 27Investing.comCSTL
      Castle Biosciences (CSTL) Rallies On Earnings Optimism, Is The Stock Still Cheap?

      Shares of Castle Biosciences (CSTL) have recently risen about 37%, following increasing agreement among Wall Street analysts on earnings estimate revisions that point to a more constructive view of the company’s earnings outlook. At around $34.11 per share, Castle Biosciences has seen strong recent momentum, with a 30 day share price return of about 39.6% and a 90 day share price return of about 54.3%. The 1 year total shareholder return of about 53.1% suggests that recent optimism around...

      Aug 27Yahoo FinanceCSTL
      Castle Biosciences CCO Tobin W sells $51,190 in stock
      Aug 26Investing.comCSTL
      Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?

      The consensus price target hints at a 31.5% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

      Aug 25Yahoo FinanceCSTL
      Castle Biosciences surges 67% after InvestingPro Fair Value call By Investing.com
      Aug 23Investing.comCSTL

      This is the newest page. Registered accounts read further back.